Overview

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Zydus Therapeutics Inc.